We are developing groundbreaking treatments based on a deep mechanistic understanding how precisely regulated Immune system and connection with Longevity (Anti-Aging). Our longevity novel oral drug molecules rejuvenate cells, and extend lifespan & healthspan.
Enzyme2 Pharmaceuticals, an Bulgarian Biotech spinoff led by Prof. Filip Fratev and Dimitar Dimitrov from Drug Discovery Factory Micar21, has developed a family of novel small-molecule oral drugs that precisely regulated Immune system. Enzyme2 opens the way for the treatment and prevention of multiple aging-associated diseases such as Alzheimer’s and Parkinson’s diseases, congestive heart failure, sarcopenia, AMD etc., utilizing a single oral agent.
The discovery of these compounds led Enzyme2 to the development of further more advanced novel agents, targeting prevention of aging-associated deterioration. Enzyme2 drug candidate ensures the perpetual rejuvenation of cells in diseased tissues, enabling, for the first time, a drug-responsive, unified targets for the prevention and treatment of multiple aging-related diseases.
Drug Discovery Factory Micar21 created the spinoff company Enzyme2 Pharmaceuticals to further develop this novel oral drug candidate into an anti-aging drug.
The demonstration of true clinical proof-of-concept is a key value-creation step in the clinical development of a medicine.
Enzyme2 is supported by a group investors who share our mutual mission of developing groundbreaking treatments and prevention of multiple aging-associated diseases.
